跳至主要内容
临床试验/NCT00540631
NCT00540631已完成3 期

A Multicentre Randomized Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of a Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of House Dust Mite (Dermatophagoides Pteronyssinus) in Patients With Rhinitis/Rhinoconjunctivitis and/or Allergic Asthma Bronchiale

Allergopharma GmbH & Co. KG2 个研究点 分布在 1 个国家目标入组 108 人开始时间: 2007年10月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
108
试验地点
2
主要终点
The primary endpoint is the change of the area under the curve (AUC)of the Symptom-Medication-Score (SMS)after 2 years of double-blind treatment to baseline

研究概览

简要总结

Multicenter Immunotherapy House Dust Mite Allergoid

详细描述

A multicentre randomized placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of a specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of house dust mite (Dermatophagoides pteronyssinus) in patients with rhinitis/rhinoconjunctivitis and/or allergic asthma bronchiale

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Positive SPT
  • Positive EAST
  • Positive specific provocation test

排除标准

  • Serious chronic diseases
  • other perennial allergies

结局指标

主要结局

The primary endpoint is the change of the area under the curve (AUC)of the Symptom-Medication-Score (SMS)after 2 years of double-blind treatment to baseline

时间窗: November 2007 - February 2010

次要结局

  • Change of the AUC of the SMS after one year to baseline.(1 year)
  • Change of Nasal Eosinophil Cationic Protein (ECP) after 2 years to baseline(2 years)
  • Immunologic changes IgE, IgG1 and IgG4(2 years)
  • Tolerability and safety of treatments during the entire study period(4 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验